<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Orencia</title><link href="http://clinicalimmunologyinfo.com/topic/orencia" rel="alternate"></link><id>http://clinicalimmunologyinfo.com/topic/orencia</id><updated>2010-11-29T15:05:09Z</updated><entry><title>Is adult mental behavior defined by childhood issues?</title><link href="http://clinicalimmunologyinfo.com/psoriasis/adult-mental-behavior-defined-childhood-issues-4474293a" rel="alternate"></link><updated>2010-11-29T15:05:09Z</updated><author><name>Helium</name></author><id>tag:clinicalimmunologyinfo.com,2010-11-29:/psoriasis/adult-mental-behavior-defined-childhood-issues-4474293a/</id><summary type="html">...</summary><category term="Autoimmune Disorders"></category><category term="Psoriasis"></category><category term="Mental Health"></category><category term="Anxiety and Panic Disorders"></category><category term="Depression"></category><category term="Medicare"></category><category term="Remicade"></category><category term="Clinical Immunology"></category><category term="Orencia"></category><category term="Skin Health"></category></entry><entry><title>UK's NICE backs wider choice of arthritis drugs</title><link href="http://clinicalimmunologyinfo.com/clinical-immunology/uks-nice-backs-wider-choice-arthritis-drugs-974503a" rel="alternate"></link><updated>2010-09-01T12:15:48Z</updated><author><name>Reuters US Online Report Health News</name></author><id>tag:clinicalimmunologyinfo.com,2010-09-01:/clinical-immunology/uks-nice-backs-wider-choice-arthritis-drugs-974503a/</id><summary type="html">&lt;div&gt;&lt;p&gt;LONDON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - &lt;a title="United Kingdom" href="/topic/United+Kingdom" &gt;Britain&lt;/a&gt;'s health cost watchdog has changed tack and recommended that rheumatoid arthritis patients should have more options if they do not respond adequately to treatment with a so-called TNF inhibitor drug.&lt;/p&gt;&lt;p&gt;The &lt;a title="National Institute for Health and Clinical Excellence" href="/topic/National+Institute+for+Health+and+Clinical+Excellen...</summary><category term="Arthritis"></category><category term="Rheumatoid Arthritis"></category><category term="Autoimmune Disorders"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Western Europe"></category><category term="Bristol-Myers Squibb Company"></category><category term="Remicade"></category><category term="Humira"></category><category term="Enbrel"></category><category term="Amgen Inc."></category><category term="Pfizer Inc."></category><category term="Reuters Group plc"></category><category term="National Institute for Health and Clinical Excellence"></category><category term="Clinical Immunology"></category><category term="Abbott Laboratories Inc."></category><category term="MabThera"></category><category term="Orencia"></category><category term="Carole Longson"></category><category term="Muscle and Skeletal Health"></category></entry></feed>
